Revolution gets selective
The group’s latest update focused on new data with the KRAS G12C inhibitor elironrasib.
FDA red and green lights: April 2025
April saw a checkpoint inhibitor bonanza for Bristol and Akeso.
AACR 2025 – Revolution shows lung promise
But half the responses with the KRAS G12D inhibitor zoldonrasib are unconfirmed.
Bristol goes pivotal with SystImmune-partnered conjugate
The first global pivotal trial will be in first-line triple-negative breast cancer.
Crispr’s Car-T crunch time
The group could soon provide clarity on CTX112’s regulatory path.
Bristol seeks another celmod use
Golcadomide will begin a new pivotal trial in follicular lymphoma.
The month ahead: April’s upcoming events
AACR approaches, along with ASCO abstract titles.
Novartis gets a PSMAfore green flag at last
Pre-chemo prostate cancer beckons, but Pluvicto has a long way to go to hit $5bn sales.
